Department of Geriatrics, Peking University People's Hospital, Beijing, China.
Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.
Eur J Pharmacol. 2022 Jul 15;927:175068. doi: 10.1016/j.ejphar.2022.175068. Epub 2022 May 27.
Whether colchicine reduces the levels of high-sensitivity C-reactive protein (hs-CRP) and interleukin-6 (IL-6) remains uncertain. Therefore, this systematic review and meta-analysis were conducted to evaluate the overall effect of colchicine treatment on hs-CRP and IL-6 levels in patients with coronary artery disease (CAD). PubMed/Medline, Embase, and the Cochrane Central Register of Controlled Trials were searched for studies published before October 2021. Clinical trials in patients with CAD with reports of hs-CRP and IL-6 level changes before and after colchicine intervention were included. In total, 11 trials on hs-CRP and two trials on IL-6 were included in this meta-analysis. Compared with that in the control group, colchicine treatment was significantly associated with decreased hs-CRP levels (weighted mean differences [WMDs], -0.81 mg/L; 95% confidence interval [CI], -1.34 to -0.28 mg/L; P = 0.003) in patients with CAD. Besides, the levels of IL-6 were significantly reduced in colchicine users compared to that of placebo (WMD, -1.28 pg/mL; 95% CI, -2.35 to -0.21 pg/mL; P = 0.02). In a subgroup analysis, colchicine led to a significant reduction in hs-CRP levels in studies with duration of intervention >7 days (WMD, -0.65 mg/L; 95% CI, -1.08 to -0.21 mg/L; P = 0.004) and studies with baseline hs-CRP levels ≥3.0 mg/L (WMD, -0.99 mg/L; 95% CI, -1.92 to -0.06 mg/L; P = 0.04). Colchicine intervention was associated with a reduction in hs-CRP and IL-6 levels in patients with CAD. Future investigations are required to verify the effect of colchicine on inflammatory markers and clarify the potential mechanisms of the cross talk between colchicine, inflammation, and cardiovascular outcomes.
秋水仙碱是否降低高敏 C 反应蛋白（hs-CRP）和白细胞介素 6（IL-6）的水平仍不确定。因此，本系统评价和荟萃分析旨在评估秋水仙碱治疗对冠心病（CAD）患者 hs-CRP 和 IL-6 水平的总体影响。检索了截止 2021 年 10 月之前发表的关于 CAD 患者秋水仙碱干预前后 hs-CRP 和 IL-6 水平变化的 PubMed/Medline、Embase 和 Cochrane 对照试验注册中心的研究。纳入了报告有秋水仙碱干预前后 hs-CRP 和 IL-6 水平变化的 CAD 患者的临床试验。本荟萃分析共纳入 11 项 hs-CRP 研究和 2 项 IL-6 研究。与对照组相比，秋水仙碱治疗与 CAD 患者 hs-CRP 水平降低显著相关（加权均数差值 [WMD]，-0.81mg/L；95%置信区间 [CI]，-1.34 至 -0.28mg/L；P=0.003）。此外，与安慰剂相比，秋水仙碱使用者的 IL-6 水平显著降低（WMD，-1.28pg/mL；95% CI，-2.35 至 -0.21pg/mL；P=0.02）。在亚组分析中，秋水仙碱干预可使干预持续时间>7 天的研究中 hs-CRP 水平显著降低（WMD，-0.65mg/L；95% CI，-1.08 至 -0.21mg/L；P=0.004）和基线 hs-CRP 水平≥3.0mg/L 的研究中 hs-CRP 水平显著降低（WMD，-0.99mg/L；95% CI，-1.92 至 -0.06mg/L；P=0.04）。秋水仙碱干预与 CAD 患者 hs-CRP 和 IL-6 水平降低相关。需要进一步研究来验证秋水仙碱对炎症标志物的影响，并阐明秋水仙碱、炎症和心血管结局之间相互作用的潜在机制。
